FOXO Technologies Inc. (FOXO) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
$'dan işlem gören FOXO Technologies Inc. (FOXO), 0 değerindeki bir Healthcare şirketidir. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 63/100 puan alıyor.
Son analiz: 17 Mar 2026FOXO Technologies Inc. (FOXO) Sağlık ve Boru Hattı Genel Bakışı
FOXO Technologies Inc. operates as a technology platform company, commercializing longevity science for the life insurance sector. Its FOXO Labs and FOXO Life platforms aim to streamline underwriting and enhance consumer engagement by integrating epigenetic biomarkers and proprietary insurance products, differentiating it within the healthcare information services industry.
Yatırım Tezi
FOXO Technologies Inc. presents a unique investment opportunity within the healthcare information services sector, driven by its focus on integrating longevity science with the life insurance industry. The company's innovative approach to simplifying underwriting and enhancing consumer engagement through its FOXO Labs and FOXO Life platforms positions it for potential growth. A key value driver is the increasing demand for personalized and data-driven insurance solutions. The company's negative profit margin of -66.5% indicates it is still in a growth phase. Upcoming catalysts include potential partnerships with major life insurance carriers and the expansion of its epigenetic biomarker testing capabilities. However, investors should be aware of the risks associated with operating in a highly regulated industry and the challenges of scaling a technology-driven business in the insurance sector.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- FOXO Technologies Inc. operates in the healthcare information services sector, focusing on longevity science.
- The company's platforms, FOXO Labs and FOXO Life, aim to improve underwriting and consumer engagement in the life insurance industry.
- FOXO's gross margin stands at 46.7%, indicating potential for profitability as the company scales.
- The company was founded in 2019 and has 102 employees.
- The company has a beta of 2.59, indicating higher volatility compared to the market.
Rakipler & Benzerleri
Güçlü Yönler
- Innovative technology platform integrating longevity science with life insurance.
- Proprietary epigenetic biomarker testing capabilities.
- Potential for strategic partnerships with major life insurance carriers.
- Focus on personalized and data-driven insurance solutions.
Zayıflıklar
- Limited operating history and small market capitalization.
- Negative profit margin and reliance on external funding.
- Dependence on regulatory approvals for its products and services.
- Competition from established players in the insurance and healthcare technology sectors.
Katalizörler
- Upcoming: Potential partnerships with major life insurance carriers to integrate FOXO's technology into their underwriting processes.
- Upcoming: Expansion of FOXO Labs services to include additional epigenetic biomarkers and testing capabilities.
- Ongoing: Development and launch of proprietary life insurance products through the FOXO Life platform.
- Ongoing: Geographic expansion into new markets in North America, Europe, and Asia.
- Ongoing: Integration with corporate wellness programs and healthcare providers to offer proactive health assessments.
Riskler
- Potential: Regulatory changes and compliance requirements impacting the life insurance and healthcare industries.
- Potential: Technological obsolescence and competition from new entrants in the longevity science and insurance technology sectors.
- Potential: Economic downturn and reduced consumer spending on life insurance products.
- Ongoing: Data security and privacy concerns related to the collection and use of personal health information.
- Ongoing: Limited operating history and small market capitalization increasing investment risk.
Büyüme Fırsatları
- Expansion of FOXO Labs Services: FOXO can grow by expanding the services offered through its FOXO Labs platform. This includes incorporating additional epigenetic biomarkers and developing more sophisticated underwriting protocols. The market for advanced underwriting solutions is estimated to reach $5 billion by 2028, presenting a significant opportunity for FOXO to capture market share. Success hinges on demonstrating the accuracy and reliability of its biomarker-based assessments.
- Strategic Partnerships with Life Insurance Carriers: Forming strategic partnerships with major life insurance carriers represents a substantial growth opportunity for FOXO. By integrating its technology into the carriers' existing underwriting processes, FOXO can gain access to a large customer base and accelerate adoption of its solutions. The life insurance market is valued at over $800 billion globally, providing ample room for growth through partnerships. These partnerships will be crucial for FOXO's market penetration and revenue generation.
- Development of Proprietary Life Insurance Products: FOXO has the opportunity to develop and launch its own proprietary life insurance products through its FOXO Life platform. These products can be designed to specifically leverage the insights gained from its epigenetic biomarker testing, offering personalized coverage options and enhanced customer engagement. The market for personalized insurance products is growing rapidly, driven by consumer demand for tailored solutions. FOXO's success in this area will depend on its ability to create innovative and competitive insurance offerings.
- Geographic Expansion: FOXO can expand its operations geographically, targeting new markets in North America, Europe, and Asia. The demand for longevity-focused healthcare solutions is growing globally, creating opportunities for FOXO to establish a presence in new regions. International expansion will require FOXO to adapt its products and services to meet local regulatory requirements and cultural preferences. This expansion could significantly increase FOXO's revenue and market reach.
- Integration with Wellness Programs: FOXO can integrate its technology with corporate wellness programs and healthcare providers to offer proactive health assessments and personalized recommendations. By providing individuals with insights into their biological age and potential health risks, FOXO can help them make informed decisions about their lifestyle and healthcare. The market for corporate wellness programs is expanding, driven by employers' desire to improve employee health and productivity. FOXO's integration with these programs could create a new revenue stream and enhance its brand awareness.
Fırsatlar
- Expansion of FOXO Labs services and product offerings.
- Geographic expansion into new markets.
- Integration with corporate wellness programs and healthcare providers.
- Development of proprietary life insurance products.
Tehditler
- Regulatory changes and compliance requirements.
- Technological obsolescence and competition from new entrants.
- Economic downturn and reduced consumer spending on life insurance.
- Data security and privacy concerns.
Rekabet Avantajları
- Proprietary technology platform that integrates longevity science with life insurance.
- Unique epigenetic biomarker testing capabilities through FOXO Labs.
- Strategic partnerships with life insurance carriers.
- First-mover advantage in the emerging market for longevity-focused insurance solutions.
FOXO Hakkında
Founded in 2019 and based in Minneapolis, Minnesota, FOXO Technologies Inc. is a technology platform company focused on revolutionizing the life insurance industry through the application of longevity science. The company's core mission is to develop products and services that seamlessly integrate longevity science with life insurance offerings, thereby improving consumer health and wellness engagement while also simplifying the often complex and cumbersome underwriting process. FOXO operates through two primary platforms: FOXO Labs and FOXO Life. FOXO Labs is a services platform designed to incorporate saliva-based epigenetic biomarkers into accelerated underwriting protocols, aiming to provide a more efficient and customer-friendly underwriting experience. FOXO Life, on the other hand, is an insurance products platform that offers both proprietary life insurance products and third-party life insurance carrier products, all of which are based on the concept of bundling longevity science with life insurance. This approach allows FOXO to offer unique and innovative insurance solutions that cater to the evolving needs of consumers in the life insurance market. FOXO's technology aims to make life insurance more accessible and relevant to a broader audience.
Ne Yaparlar
- Develops a technology platform focused on longevity science.
- Integrates epigenetic biomarkers into life insurance underwriting.
- Offers saliva-based epigenetic testing through FOXO Labs.
- Provides proprietary and third-party life insurance products through FOXO Life.
- Aims to simplify the consumer underwriting journey.
- Enhances consumer health and wellness engagement.
İş Modeli
- Generates revenue through FOXO Labs by providing epigenetic biomarker testing services to life insurance companies.
- Earns revenue through FOXO Life by selling proprietary life insurance products.
- Collects fees from third-party life insurance carriers for offering their products on its platform.
- Partnerships with insurance companies to integrate FOXO's technology into their underwriting processes.
Sektör Bağlamı
FOXO Technologies Inc. operates within the healthcare information services industry, a sector experiencing rapid growth due to technological advancements and increasing demand for personalized healthcare solutions. The integration of data analytics and AI in healthcare is transforming traditional practices, creating opportunities for companies like FOXO to innovate. The competitive landscape includes established players in the insurance and healthcare technology sectors, as well as emerging companies focused on longevity science. FOXO's unique approach of combining epigenetic biomarkers with life insurance products differentiates it from competitors. The market for personalized insurance solutions is expanding, driven by consumer demand for tailored products and services.
Kilit Müşteriler
- Life insurance companies seeking to improve their underwriting processes.
- Consumers interested in personalized life insurance products based on longevity science.
- Healthcare providers looking to offer proactive health assessments to their patients.
- Corporate wellness programs seeking to enhance employee health and well-being.
Finansallar
Grafik & Bilgi
FOXO Technologies Inc. (FOXO) hisse senedi fiyatı: Price data unavailable
Son Haberler
-
12 Information Technology Stocks Moving In Tuesday's After-Market Session
benzinga · 6 May 2025
-
Crude Oil Rises Sharply; US Trade Deficit Widens In March
benzinga · 6 May 2025
-
12 Information Technology Stocks Moving In Thursday's Intraday Session
benzinga · 17 Nis 2025
-
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
benzinga · 11 Kas 2024
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
FOXO için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
FOXO için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, FOXO'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Son Haberler
12 Information Technology Stocks Moving In Tuesday's After-Market Session
Crude Oil Rises Sharply; US Trade Deficit Widens In March
12 Information Technology Stocks Moving In Thursday's Intraday Session
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
Yönetim: Seamus Lagan
CEO
Seamus Lagan is the CEO of FOXO Technologies Inc. His background includes experience in managing and scaling technology-driven companies. He has a proven track record in strategic leadership and business development. Lagan's expertise lies in driving innovation and commercializing new technologies. He is responsible for overseeing the company's overall strategy and operations. His leadership is focused on executing FOXO's vision of transforming the life insurance industry through longevity science.
Sicil: Under Seamus Lagan's leadership, FOXO Technologies Inc. has focused on developing its FOXO Labs and FOXO Life platforms. Key milestones include the integration of epigenetic biomarkers into underwriting protocols and the launch of proprietary life insurance products. Lagan has been instrumental in securing partnerships and driving the company's growth strategy. His focus on innovation and customer engagement has positioned FOXO for success in the evolving life insurance market.
FOXO OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that FOXO Technologies Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, which increases investment risk. Trading on the OTC Other tier typically involves less stringent listing requirements compared to exchanges like the NYSE or NASDAQ, resulting in a higher degree of speculative activity and potential for price volatility.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure and transparency.
- Higher potential for fraud and manipulation.
- Lower trading volume and liquidity.
- Greater price volatility.
- Increased risk of delisting or suspension of trading.
- Verify the company's registration and regulatory filings.
- Review available financial statements and disclosures.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Company has a registered business address and contact information.
- Company has a functioning website and social media presence.
- Company has a management team with relevant experience.
- Company has a clear business plan and revenue model.
- Company has received positive media coverage or industry recognition.
FOXO Hakkında Sıkça Sorulan Sorular
FOXO için değerlendirilmesi gereken temel faktörler nelerdir?
FOXO Technologies Inc. (FOXO) şu anda yapay zeka skoru 63/100, orta puanı gösteriyor. Temel güçlü yan: Innovative technology platform integrating longevity science with life insurance.. İzlenmesi gereken birincil risk: Potential: Regulatory changes and compliance requirements impacting the life insurance and healthcare industries.. Bu bir finansal tavsiye değildir.
FOXO MoonshotScore'u nedir?
FOXO şu anda MoonshotScore'da 63/100 (Derece B) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
FOXO verileri ne sıklıkla güncellenir?
FOXO fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler FOXO hakkında ne diyor?
FOXO için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
FOXO'a yatırım yapmanın riskleri nelerdir?
FOXO için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Regulatory changes and compliance requirements impacting the life insurance and healthcare industries.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
FOXO'ın P/E oranı nedir?
FOXO için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için FOXO'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
FOXO aşırı değerli mi, yoksa düşük değerli mi?
FOXO Technologies Inc. (FOXO)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
FOXO'ın temettü verimi nedir?
FOXO Technologies Inc. (FOXO) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Financial data is limited due to the company's OTC listing and disclosure status.
- AI analysis is pending, so analyst consensus is unavailable.